• EyePoint, Inc. reported first-quarter 2026 results on May 6, 2026, with revenue of US$696,000 versus US$24.45 million a year earlier and a net loss of US$84.83 million, or US$0.99 per basic and diluted share from continuing operations, compared with a loss of US$45.2 million, or US$0.65 per share, in the prior-year quarter.
• The company highlighted that its DURAVYU Phase 3 programs in wet age-related macular degeneration and diabetic macular edema are progressing on schedule, supported by US$223 million in cash and investments as of March 31, 2026, which it expects to fund operations into the fourth quarter of 2027.
• We’ll now examine how EyePoint’s sharply lower revenue but continued DURAVYU Phase 3 investment and extended cash runway influence its investment narrative.

Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

EyePoint Investment Narrative Recap

To own EyePoint, you need to believe DURAVYU can eventually turn a loss-making, near zero revenue business into a commercial retina player, despite heavy current cash burn. The latest quarter’s steep revenue drop and wider loss support the idea that the DURAVYU Phase 3 readouts remain the key near term catalyst, while the main risk is that extended losses outpace EyePoint’s projected cash runway into the fourth quarter of 2027.

Against that backdrop, the March 2026 update that DURAVYU’s Phase 3 trials in wet AMD (LUGANO, LUCIA) and DME (COMO, CAPRI) are progressing on schedule is highly relevant. It ties directly to why EyePoint is absorbing an US$84.83 million quarterly loss and relying on its US$223 million cash and investments, as these trials underpin both the potential inflection in future revenue and the risk of prolonged cash burn if outcomes disappoint.

Yet beneath the promise of DURAVYU, the combination of Q1 revenue of just US$696,000 and rising operating losses highlights a financing risk that investors should be aware of if...

EyePoint's narrative projects $260.9 million revenue and $49.2 million earnings by 2029.

Uncover how EyePoint's forecasts yield a $37.17 fair value, a 177% upside to its current price.

Exploring Other Perspectives

Before this weak Q1, the most bearish analysts were already assuming only about 7.9 percent annual revenue growth and ongoing losses, so if DURAVYU stumbles or is slower to scale, their more cautious view of cash burn and potential dilution could end up closer to reality than the consensus expects.

Explore 3 other fair value estimates on EyePoint - why the stock might be worth just $37.17!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your EyePoint research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free EyePoint research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate EyePoint's overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.